| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Tumor Microenvironment |
Institute of Developmental Biology and Cancer Research University of Nice, Centre National de la Recherche Scientifique UMR 6543, Centre A. Lacassagne, Nice, France
Requests for reprints: Jacques Pouyssegur, Centre National de la Recherche Scientifique UMR 6543, 33 Avenue Valombrose, Nice 06189, France. Phone: 33-492-03-1222; Fax: 33-492-03-1225; E-mail: pouysseg{at}unice.fr.
Key Words: carbonic anhydrase hypoxia-inducible factor pH homeostasis tumor growth tumor microenvironment
Acidosis of the tumor microenvironment is typical of a malignant phenotype, particularly in hypoxic tumors. All cells express multiple isoforms of carbonic anhydrase (CA), enzymes catalyzing the reversible hydration of carbon dioxide into bicarbonate and protons. Tumor cells express membrane-bound CAIX and CAXII that are controlled via the hypoxia-inducible factor (HIF). Despite the recognition that tumor expression of HIF-1
and CAIX correlates with poor patient survival, the role of CAIX and CAXII in tumor growth is not fully resolved. To understand the advantage that tumor cells derive from expression of both CAIX and CAXII, we set up experiments to either force or invalidate the expression of these enzymes. In hypoxic LS174Tr tumor cells expressing either one or both CA isoforms, we show that (a) in response to a "CO2 load," both CAs contribute to extracellular acidification and (b) both contribute to maintain a more alkaline resting intracellular pH (pHi), an action that preserves ATP levels and cell survival in a range of acidic outside pH (6.0–6.8) and low bicarbonate medium. In vivo experiments show that ca9 silencing alone leads to a 40% reduction in xenograft tumor volume with up-regulation of ca12 mRNA levels, whereas invalidation of both CAIX and CAXII gives an impressive 85% reduction. Thus, hypoxia-induced CAIX and CAXII are major tumor prosurvival pHi-regulating enzymes, and their combined targeting shows that they hold potential as anticancer targets. [Cancer Res 2009;69(1):358–68]
This article has been cited by other articles:
![]() |
P. Hersey, R. N. Watts, X. D. Zhang, and J. Hackett Metabolic Approaches to Treatment of Melanoma Clin. Cancer Res., November 1, 2009; 15(21): 6490 - 6494. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Alterio, M. Hilvo, A. Di Fiore, C. T. Supuran, P. Pan, S. Parkkila, A. Scaloni, J. Pastorek, S. Pastorekova, C. Pedone, et al. Crystal structure of the catalytic domain of the tumor-associated human carbonic anhydrase IX PNAS, September 22, 2009; 106(38): 16233 - 16238. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Swietach, S. Patiar, C. T. Supuran, A. L. Harris, and R. D. Vaughan-Jones The Role of Carbonic Anhydrase 9 in Regulating Extracellular and Intracellular pH in Three-dimensional Tumor Cell Growths J. Biol. Chem., July 24, 2009; 284(30): 20299 - 20310. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. HARGUINDEY, J. L. ARRANZ, M. L. WAHL, G. ORIVE, and S. J. RESHKIN Proton Transport Inhibitors as Potentially Selective Anticancer Drugs Anticancer Res, June 1, 2009; 29(6): 2127 - 2136. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Brahimi-Horn and J. Pouyssegur HIF at a glance J. Cell Sci., April 15, 2009; 122(8): 1055 - 1057. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |